Structural Basis for Binding and Selectivity of Antimalarial and Anticancer Ethylenediamine Inhibitors to Protein Farnesyltransferase

Michael A. Hast, Steven Fletcher, Christopher G. Cummings, Erin E. Pusateri, Michelle A. Blaskovich, Kasey Rivas, Michael H. Gelb, Wesley C. Van Voorhis, Said M. Sebti, Andrew Hamilton, Lorena S. Beese

Research output: Contribution to journalArticle

Abstract

Protein farnesyltransferase (FTase) catalyzes an essential posttranslational lipid modification of more than 60 proteins involved in intracellular signal transduction networks. FTase inhibitors have emerged as a significant target for development of anticancer therapeutics and, more recently, for the treatment of parasitic diseases caused by protozoan pathogens, including malaria (Plasmodium falciparum). We present the X-ray crystallographic structures of complexes of mammalian FTase with five inhibitors based on an ethylenediamine scaffold, two of which exhibit over 1000-fold selective inhibition of P. falciparum FTase. These structures reveal the dominant determinants in both the inhibitor and enzyme that control binding and selectivity. Comparison to a homology model constructed for the P. falciparum FTase suggests opportunities for further improving selectivity of a new generation of antimalarial inhibitors.

Original languageEnglish (US)
Pages (from-to)181-192
Number of pages12
JournalChemistry and Biology
Volume16
Issue number2
DOIs
StatePublished - Feb 27 2009

Fingerprint

ethylenediamine
Farnesyltranstransferase
Antimalarials
Plasmodium falciparum
Signal transduction
Parasitic Diseases
Falciparum Malaria
Enzyme Inhibitors
Pathogens
Post Translational Protein Processing
Scaffolds
Signal Transduction
X-Rays
Lipids
X rays
p21(ras) farnesyl-protein transferase

Keywords

  • CHEMBIO
  • MICROBIO
  • PROTEINS

ASJC Scopus subject areas

  • Biochemistry
  • Drug Discovery
  • Molecular Biology
  • Clinical Biochemistry
  • Molecular Medicine
  • Pharmacology

Cite this

Hast, M. A., Fletcher, S., Cummings, C. G., Pusateri, E. E., Blaskovich, M. A., Rivas, K., ... Beese, L. S. (2009). Structural Basis for Binding and Selectivity of Antimalarial and Anticancer Ethylenediamine Inhibitors to Protein Farnesyltransferase. Chemistry and Biology, 16(2), 181-192. https://doi.org/10.1016/j.chembiol.2009.01.014

Structural Basis for Binding and Selectivity of Antimalarial and Anticancer Ethylenediamine Inhibitors to Protein Farnesyltransferase. / Hast, Michael A.; Fletcher, Steven; Cummings, Christopher G.; Pusateri, Erin E.; Blaskovich, Michelle A.; Rivas, Kasey; Gelb, Michael H.; Van Voorhis, Wesley C.; Sebti, Said M.; Hamilton, Andrew; Beese, Lorena S.

In: Chemistry and Biology, Vol. 16, No. 2, 27.02.2009, p. 181-192.

Research output: Contribution to journalArticle

Hast, MA, Fletcher, S, Cummings, CG, Pusateri, EE, Blaskovich, MA, Rivas, K, Gelb, MH, Van Voorhis, WC, Sebti, SM, Hamilton, A & Beese, LS 2009, 'Structural Basis for Binding and Selectivity of Antimalarial and Anticancer Ethylenediamine Inhibitors to Protein Farnesyltransferase', Chemistry and Biology, vol. 16, no. 2, pp. 181-192. https://doi.org/10.1016/j.chembiol.2009.01.014
Hast, Michael A. ; Fletcher, Steven ; Cummings, Christopher G. ; Pusateri, Erin E. ; Blaskovich, Michelle A. ; Rivas, Kasey ; Gelb, Michael H. ; Van Voorhis, Wesley C. ; Sebti, Said M. ; Hamilton, Andrew ; Beese, Lorena S. / Structural Basis for Binding and Selectivity of Antimalarial and Anticancer Ethylenediamine Inhibitors to Protein Farnesyltransferase. In: Chemistry and Biology. 2009 ; Vol. 16, No. 2. pp. 181-192.
@article{57d7f7c439214f4d8e4104c2982c2644,
title = "Structural Basis for Binding and Selectivity of Antimalarial and Anticancer Ethylenediamine Inhibitors to Protein Farnesyltransferase",
abstract = "Protein farnesyltransferase (FTase) catalyzes an essential posttranslational lipid modification of more than 60 proteins involved in intracellular signal transduction networks. FTase inhibitors have emerged as a significant target for development of anticancer therapeutics and, more recently, for the treatment of parasitic diseases caused by protozoan pathogens, including malaria (Plasmodium falciparum). We present the X-ray crystallographic structures of complexes of mammalian FTase with five inhibitors based on an ethylenediamine scaffold, two of which exhibit over 1000-fold selective inhibition of P. falciparum FTase. These structures reveal the dominant determinants in both the inhibitor and enzyme that control binding and selectivity. Comparison to a homology model constructed for the P. falciparum FTase suggests opportunities for further improving selectivity of a new generation of antimalarial inhibitors.",
keywords = "CHEMBIO, MICROBIO, PROTEINS",
author = "Hast, {Michael A.} and Steven Fletcher and Cummings, {Christopher G.} and Pusateri, {Erin E.} and Blaskovich, {Michelle A.} and Kasey Rivas and Gelb, {Michael H.} and {Van Voorhis}, {Wesley C.} and Sebti, {Said M.} and Andrew Hamilton and Beese, {Lorena S.}",
year = "2009",
month = "2",
day = "27",
doi = "10.1016/j.chembiol.2009.01.014",
language = "English (US)",
volume = "16",
pages = "181--192",
journal = "Cell Chemical Biology",
issn = "2451-9448",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Structural Basis for Binding and Selectivity of Antimalarial and Anticancer Ethylenediamine Inhibitors to Protein Farnesyltransferase

AU - Hast, Michael A.

AU - Fletcher, Steven

AU - Cummings, Christopher G.

AU - Pusateri, Erin E.

AU - Blaskovich, Michelle A.

AU - Rivas, Kasey

AU - Gelb, Michael H.

AU - Van Voorhis, Wesley C.

AU - Sebti, Said M.

AU - Hamilton, Andrew

AU - Beese, Lorena S.

PY - 2009/2/27

Y1 - 2009/2/27

N2 - Protein farnesyltransferase (FTase) catalyzes an essential posttranslational lipid modification of more than 60 proteins involved in intracellular signal transduction networks. FTase inhibitors have emerged as a significant target for development of anticancer therapeutics and, more recently, for the treatment of parasitic diseases caused by protozoan pathogens, including malaria (Plasmodium falciparum). We present the X-ray crystallographic structures of complexes of mammalian FTase with five inhibitors based on an ethylenediamine scaffold, two of which exhibit over 1000-fold selective inhibition of P. falciparum FTase. These structures reveal the dominant determinants in both the inhibitor and enzyme that control binding and selectivity. Comparison to a homology model constructed for the P. falciparum FTase suggests opportunities for further improving selectivity of a new generation of antimalarial inhibitors.

AB - Protein farnesyltransferase (FTase) catalyzes an essential posttranslational lipid modification of more than 60 proteins involved in intracellular signal transduction networks. FTase inhibitors have emerged as a significant target for development of anticancer therapeutics and, more recently, for the treatment of parasitic diseases caused by protozoan pathogens, including malaria (Plasmodium falciparum). We present the X-ray crystallographic structures of complexes of mammalian FTase with five inhibitors based on an ethylenediamine scaffold, two of which exhibit over 1000-fold selective inhibition of P. falciparum FTase. These structures reveal the dominant determinants in both the inhibitor and enzyme that control binding and selectivity. Comparison to a homology model constructed for the P. falciparum FTase suggests opportunities for further improving selectivity of a new generation of antimalarial inhibitors.

KW - CHEMBIO

KW - MICROBIO

KW - PROTEINS

UR - http://www.scopus.com/inward/record.url?scp=60849087366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60849087366&partnerID=8YFLogxK

U2 - 10.1016/j.chembiol.2009.01.014

DO - 10.1016/j.chembiol.2009.01.014

M3 - Article

VL - 16

SP - 181

EP - 192

JO - Cell Chemical Biology

JF - Cell Chemical Biology

SN - 2451-9448

IS - 2

ER -